BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with MTAP-deleted non-small cell lung cancer (NSCLC), according to results from the Phase 1CA240-0007 trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

— Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Researchers at CIC bioGUNE, led by Prof. José M. Mato and Dr. Óscar Millet, have developed a “metabolic aging clock” that uses a simple blood test to predict biological age and detect early signs of disease. Published in npj Metabolic Health and Disease, the tool leverages NMR metabolomics and machine learning to analyze small molecules in the blood, providing a more accurate measure of health than chronological age.

Developed with data from over 13,500 participants in the AKRIBEA cohort (Basque Country), the clock can reveal discrepancies between metabolic and chronological age, potentially signaling early disease. For example, prostate cancer patients showed a metabolic age nearly 5 years older than their actual age, while those with fatty liver disease had a difference of over 14 years. The system also detects subtype-specific disease patterns that traditional tests may miss.

Beyond aging, the platform can estimate 25+ clinical parameters, such as inflammation or kidney function, from the same blood sample, offering a non-invasive, personalized health assessment. The team aims to further validate the tool for broader use in healthcare, supporting early detection, risk stratification, and healthier aging.